CD19xCD3 Bispecific Antibody for Pediatric Leukemia

Solution Overview

Problem

Current treatments for pediatric acute lymphoblastic leukemia (ALL) are inadequate in managing relapsed cases, particularly those refractory to conventional therapies like chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), due to resistance of leukemic cells and reduced patient tolerance to second-line treatments, leading to lower remission rates and higher relapse incidence.

Innovation Solution

Administration of a CD19×CD3 bispecific single chain antibody construct, which engages T cells to target CD19+ ALL blasts, inducing a graft-versus-leukemia effect without graft-versus-host disease, providing a non-chemotherapeutic and less toxic treatment option.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intensified poly chemotherapy is used to induce second complete remission, then remission rate improves, but patient tolerance deteriorates and chemotherapy-related toxicity increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical/chemical chemotherapy system with an immunological system. The CD19×CD3 bispecific antibody activates the patient's own T cells to recognize and eliminate leukemic cells, substituting chemical cytotoxicity with biological immunity. This resolves the contradiction by achieving anti-leukemic effect without chemotherapy-related toxicity.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The CD19×CD3 bispecific antibody acts as an intermediary that bridges T cells (effector cells) and leukemic cells (target cells). The antibody's dual specificity allows it to simultaneously bind CD3 on T cells and CD19 on leukemic cells, facilitating specific immune recognition and elimination of leukemic cells without requiring chemotherapy.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If conventional chemotherapy and HSCT are used for relapsed ALL, then initial treatment efficacy is achieved, but leukemic cell resistance develops

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent replaces chemotherapy-based treatment with T cell-mediated immunotherapy. Since the mechanism of action is fundamentally different (immunological recognition vs. chemical cytotoxicity), leukemic cells that are resistant to chemotherapy remain sensitive to T cell attack, thereby overcoming resistance while maintaining treatment efficacy.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the fundamental parameter of treatment mechanism from chemical to biological. By shifting from chemotherapy (chemical agents) to adoptive T cell therapy (biological system), the treatment bypasses chemical resistance mechanisms while preserving therapeutic effectiveness.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If a second round of intensive therapy is administered, then remission may be induced, but patient tolerance to treatment deteriorates

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent substitutes intensive chemotherapy with a more tolerable immunological approach. The CD19×CD3 antibody-mediated T cell activation achieves remission induction through biological immunity rather than chemical toxicity, maintaining therapeutic effectiveness while significantly improving patient tolerance.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

4Reliability

If allogeneic HSCT is used for chemorefractory relapse, then curative potential is achieved, but graft-versus-host disease risk increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent replaces allogeneic HSCT with autologous T cell therapy using the patient's own cells. This eliminates the source of graft-versus-host disease (allogeneic donor cells) while preserving the curative potential of intensive anti-leukemic therapy through patient-specific T cell activation.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The CD19×CD3 bispecific antibody serves as an intermediary that activates the patient's own T cells without requiring allogeneic donor cells. This eliminates the need for HSCT and its associated graft-versus-host disease risk, while achieving comparable or superior curative potential through targeted immune activation.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CD19×CD3 bispecific single chain antibody effectively eliminates leukemic cells, achieving complete remissions and converting MRD-positive status to MRD-negative in pediatric ALL patients, reducing relapse risk and avoiding chemotherapy-related toxicity.

Implementation Method 1

a CD19×CD3 bispecific single chain antibody construct, which engages T cells to target CD19+ ALL blasts

Methodology Applied
Scientific EffectBispecific antibody binding:

Implementation Method 2

inducing a graft-versus-leukemia effect without graft-versus-host disease

Methodology Applied
Scientific EffectGraft-versus-leukemia effect:

Data Source

PatentUS20230235053A1Treatment of pediatric acute lymphoblastic leukemia
Publication Date: 2023.07.27
  • US20230235053A1 patent drawing
  • US20230235053A1 patent drawing
  • US20230235053A1 patent drawing

AI summary

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.